Conclusion and results
Four weeks after treatment initiation, the lesions began to regress, and after two months, complete clearance was achieved, leaving behind residual postinflammatory hypopigmentation. The dose of CsA was tapered to 25 mg every other day for an additional month before discontinuation. The patient did not experience any adverse effects and had no recurrence during the three-month follow-up after stopping CsA.